|
Market Closed -
Nasdaq
00:00:00 03/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 2.320 USD | +0.87% |
|
-1.28% | +136.11% |
Company Valuation: Fate Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,587 | 980.4 | 368.8 | 187.9 | 113.3 | 278 | - | - |
| Change | - | -82.45% | -62.39% | -49.04% | -39.69% | 145.25% | - | - |
| Enterprise Value (EV) | 4,971 | 544.2 | 53.6 | -118.8 | 113.3 | 278 | 278 | 278 |
| Change | - | -89.05% | -90.15% | -321.66% | 195.41% | 145.25% | 0% | 0% |
| P/E | -26.1x | -3.47x | -2.28x | -1.01x | -0.85x | -2.17x | -2.24x | -2.06x |
| PBR | 8.25x | 2.03x | 0.98x | 0.59x | - | - | - | - |
| PEG | - | -0.1x | 0.1x | - | 0x | 0.3x | 0.72x | -0.24x |
| Capitalization / Revenue | 100x | 10.2x | 5.8x | 13.8x | 17.1x | 49.2x | 58.3x | 69.4x |
| EV / Revenue | 0x | 0x | 0x | -0x | 0x | 49.2x | 58.3x | 69.4x |
| EV / EBITDA | -0x | -0x | -0x | 0x | -0x | -2.33x | -1.82x | - |
| EV / EBIT | -0x | -0x | -0x | 0x | -0x | -2.06x | -1.83x | -1.55x |
| EV / FCF | -0x | -0x | -0x | 0x | -0x | -2.5x | -2.36x | -2.04x |
| FCF Yield | -3.82% | -28.9% | -37.5% | -65.8% | -98.8% | -39.9% | -42.4% | -48.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.24 | -2.91 | -1.64 | -1.64 | -1.15 | -1.068 | -1.035 | -1.124 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 55.85 | 96.3 | 63.53 | 13.63 | 6.646 | 5.649 | 4.767 | 4.008 |
| EBITDA 1 | -211.1 | -294.6 | -172.2 | -191.3 | -134.8 | -119.3 | -153.1 | - |
| EBIT 1 | -217 | -308.4 | -190.5 | -210.3 | -147.7 | -134.7 | -151.5 | -178.9 |
| Net income 1 | -212.2 | -281.7 | -160.9 | -186.3 | -136.3 | -128.8 | -146 | -179 |
| Net Debt | -615.9 | -436.2 | -315.2 | -306.7 | - | - | - | - |
| Reference price 2 | 58.510 | 10.090 | 3.740 | 1.650 | 0.983 | 2.320 | 2.320 | 2.320 |
| Nbr of stocks (in thousands) | 95,494 | 97,170 | 98,602 | 113,894 | 115,352 | 119,821 | - | - |
| Announcement Date | 28/02/22 | 28/02/23 | 26/02/24 | 05/03/25 | 26/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.17x | - | - | -.--% | 278M | |
| 21.73x | 7.71x | 15.48x | 1.37% | 74.16B | |
| 29.82x | 8.57x | 26.7x | 0.04% | 57.39B | |
| 32.98x | 5.93x | 17.77x | 0.98% | 47.64B | |
| -21.31x | 230.81x | -22.97x | -.--% | 44.29B | |
| 33.26x | 3.23x | 13.97x | -.--% | 42.5B | |
| 46.77x | 5.41x | 29.66x | -.--% | 40.71B | |
| 27.63x | 7.93x | 20.48x | 0.41% | 30.97B | |
| 32.99x | 7.05x | 18.3x | -.--% | 28.53B | |
| -15.1x | 5.68x | -7.14x | -.--% | 24.34B | |
| Average | 18.66x | 31.37x | 12.47x | 0.28% | 39.08B | |
| Weighted average by Cap. | 22.25x | 32.04x | 13.55x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- FATE Stock
- Valuation Fate Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
